The scientist who pioneered KRAS drugs has a new idea about making them more powerful
It’s only been nine years since Kevan Shokat’s group at the University of California, San Francisco published the seminal paper breaking the “undruggable” spell thought to ensnare KRAS, one of the most common oncogenes. In less than a decade — breakneck speed by drug development standards — the space went from utterly barren to having one approved drug, plus a close rival ready to duke it out.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.